Montreux, Switzerland | June 7, 2023 –
CYTEA|BIO, a pre-clinical stage biotech company developing therapeutic antibody-effector cell constructs, is pleased to announce the formation of its Clinical Steering Group for the planning and execution of clinical activities for the PIN™ platform NK cell treatment for Glioblastoma Multiforme.
Dr. Roger Stupp is an internationally recognized medical oncologist who has made significant contributions to the field of oncology. He is particularly known for his groundbreaking research in the treatment of glioblastoma.
Dr. Roger Stupp’s research has led to the development of two novel treatments that have received FDA approval and are now considered the standard of care for patients suffering from glioblastoma.
He is the Paul Bucy Professor of Neurological Surgery, and Professor of Medicine (Hematology/Oncology) and Neurology at Northwestern University in Chicago. He serves as Associate Director for the Lurie Comprehensive Cancer Center and Co- Director of the Malnati Brain Tumor Institute. He is the chief of the Division of Neuro-Oncology at Northwestern Medicine.
CYTEA|BIO is a pre-clinical stage biotech company developing therapeutic antibody-effector cell constructs by combining Fc-engineered targeting ligands with unmodified allogeneic effector cells via natural receptors. The patented Pin™ platform enables practically limitless combinations of effector mechanisms and targeting ligands, building new and innovative therapies without need for drug discovery, with unrivalled efficacy, safety and manufacturing / regulatory economics. The company is the first pipeline company of MedXCell.
Lionel Brodard, CFO